- Home
- NTRB vs BYSI Comparison
NTRB vs BYSI Comparison
Compare NTRB & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | BYSI |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 79.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | NTRB | BYSI |
|---|---|---|
| Price | $4.62 | $1.97 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 21.2K | ★ 23.1K |
| Earning Date | 12-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,578,059.00 | N/A |
| Revenue This Year | $560.75 | N/A |
| Revenue Next Year | $588.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.92 | N/A |
| 52 Week Low | $3.72 | $0.98 |
| 52 Week High | $11.78 | $3.44 |
Technical Indicators
Market Signals| Indicator | NTRB | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 49.57 |
| Support Level | $4.59 | $1.83 |
| Resistance Level | $4.99 | $2.21 |
| Average True Range (ATR) | 0.30 | 0.20 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 0.83 | 50.58 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.